The prevalence of tumour markers in malignant pleural effusions associated with primary pulmonary adenocarcinoma: a retrospective study

Background Oncological treatment of primary pulmonary adenocarcinoma (AC) includes drugs targeting the pathways involving programmed death-ligand 1 (PD-L1), epidermal growth factor receptor (EGFR) mutation and anaplastic lymphoma kinase (ALK). The aim of the study was to report the prevalence of the...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Katrine Fjaellegaard, Jesper Koefod Petersen, Gitte Andersen, Matteo Biagini, Rahul Bhatnagar, Christian B. Laursen, Paul Frost Clementsen, Uffe Bodtger
Formato:	article
Lenguaje:	EN
Publicado:	Taylor & Francis Group 2021
Materias:	lung cancer pulmonary adenocarcinoma malignant pleural effusion tumour markers programmed death-ligand 1 (pd-l1) epidermal growth factor receptor (egfr) mutation anaplastic lymphoma kinase (alk) Diseases of the respiratory system RC705-779
Acceso en línea:	https://doaj.org/article/fa3b9a0ed358441988e550197fcf6b46
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:fa3b9a0ed358441988e550197fcf6b46
record_format	dspace
spelling	oai:doaj.org-article:fa3b9a0ed358441988e550197fcf6b462021-11-04T15:00:43ZThe prevalence of tumour markers in malignant pleural effusions associated with primary pulmonary adenocarcinoma: a retrospective study2001-852510.1080/20018525.2021.1984375https://doaj.org/article/fa3b9a0ed358441988e550197fcf6b462021-01-01T00:00:00Zhttp://dx.doi.org/10.1080/20018525.2021.1984375https://doaj.org/toc/2001-8525Background Oncological treatment of primary pulmonary adenocarcinoma (AC) includes drugs targeting the pathways involving programmed death-ligand 1 (PD-L1), epidermal growth factor receptor (EGFR) mutation and anaplastic lymphoma kinase (ALK). The aim of the study was to report the prevalence of these tumour markers in pleural fluid with cytology positive for pulmonary AC and the potential influence of volume pleural fluid tested. Methods We retrospectively reviewed all thoracenteses performed in a two-year period at our interventional unit at Department of Respiratory Medicine at Zealand University Hospital Naestved, Denmark. ALK and PD-L1 testing was done using immunohistochemistry and EGFR testing using next-generation sequencing. We included pleural fluid specimens containing malignant cells originating from primary pulmonary AC and with at least one tumour marker requested by the clinicians. Results When screening 927 pleural fluid specimens, we identified 57 in accordance with the inclusion criteria. PD-L1, ALK and EGFR were obtained in 35/55 (64%), 38/57 (67%) and 26/47 (55%), respectively. The prevalence did not increase when analysing volumes > 50 mL (p = 0.21–0.58) Conclusion Tumour markers in pleural fluid specimens containing cells from pulmonary AC can be demonstrated in more than half of the cases. Therefore, supplementary invasive procedures than thoracentesis could potentially await these analyses.Katrine FjaellegaardJesper Koefod PetersenGitte AndersenMatteo BiaginiRahul BhatnagarChristian B. LaursenPaul Frost ClementsenUffe BodtgerTaylor & Francis Grouparticlelung cancerpulmonary adenocarcinomamalignant pleural effusiontumour markersprogrammed death-ligand 1 (pd-l1)epidermal growth factor receptor (egfr) mutationanaplastic lymphoma kinase (alk)Diseases of the respiratory systemRC705-779ENEuropean Clinical Respiratory Journal, Vol 8, Iss 1 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	lung cancer pulmonary adenocarcinoma malignant pleural effusion tumour markers programmed death-ligand 1 (pd-l1) epidermal growth factor receptor (egfr) mutation anaplastic lymphoma kinase (alk) Diseases of the respiratory system RC705-779
spellingShingle	lung cancer pulmonary adenocarcinoma malignant pleural effusion tumour markers programmed death-ligand 1 (pd-l1) epidermal growth factor receptor (egfr) mutation anaplastic lymphoma kinase (alk) Diseases of the respiratory system RC705-779 Katrine Fjaellegaard Jesper Koefod Petersen Gitte Andersen Matteo Biagini Rahul Bhatnagar Christian B. Laursen Paul Frost Clementsen Uffe Bodtger The prevalence of tumour markers in malignant pleural effusions associated with primary pulmonary adenocarcinoma: a retrospective study
description	Background Oncological treatment of primary pulmonary adenocarcinoma (AC) includes drugs targeting the pathways involving programmed death-ligand 1 (PD-L1), epidermal growth factor receptor (EGFR) mutation and anaplastic lymphoma kinase (ALK). The aim of the study was to report the prevalence of these tumour markers in pleural fluid with cytology positive for pulmonary AC and the potential influence of volume pleural fluid tested. Methods We retrospectively reviewed all thoracenteses performed in a two-year period at our interventional unit at Department of Respiratory Medicine at Zealand University Hospital Naestved, Denmark. ALK and PD-L1 testing was done using immunohistochemistry and EGFR testing using next-generation sequencing. We included pleural fluid specimens containing malignant cells originating from primary pulmonary AC and with at least one tumour marker requested by the clinicians. Results When screening 927 pleural fluid specimens, we identified 57 in accordance with the inclusion criteria. PD-L1, ALK and EGFR were obtained in 35/55 (64%), 38/57 (67%) and 26/47 (55%), respectively. The prevalence did not increase when analysing volumes > 50 mL (p = 0.21–0.58) Conclusion Tumour markers in pleural fluid specimens containing cells from pulmonary AC can be demonstrated in more than half of the cases. Therefore, supplementary invasive procedures than thoracentesis could potentially await these analyses.
format	article
author	Katrine Fjaellegaard Jesper Koefod Petersen Gitte Andersen Matteo Biagini Rahul Bhatnagar Christian B. Laursen Paul Frost Clementsen Uffe Bodtger
author_facet	Katrine Fjaellegaard Jesper Koefod Petersen Gitte Andersen Matteo Biagini Rahul Bhatnagar Christian B. Laursen Paul Frost Clementsen Uffe Bodtger
author_sort	Katrine Fjaellegaard
title	The prevalence of tumour markers in malignant pleural effusions associated with primary pulmonary adenocarcinoma: a retrospective study
title_short	The prevalence of tumour markers in malignant pleural effusions associated with primary pulmonary adenocarcinoma: a retrospective study
title_full	The prevalence of tumour markers in malignant pleural effusions associated with primary pulmonary adenocarcinoma: a retrospective study
title_fullStr	The prevalence of tumour markers in malignant pleural effusions associated with primary pulmonary adenocarcinoma: a retrospective study
title_full_unstemmed	The prevalence of tumour markers in malignant pleural effusions associated with primary pulmonary adenocarcinoma: a retrospective study
title_sort	prevalence of tumour markers in malignant pleural effusions associated with primary pulmonary adenocarcinoma: a retrospective study
publisher	Taylor & Francis Group
publishDate	2021
url	https://doaj.org/article/fa3b9a0ed358441988e550197fcf6b46
work_keys_str_mv	AT katrinefjaellegaard theprevalenceoftumourmarkersinmalignantpleuraleffusionsassociatedwithprimarypulmonaryadenocarcinomaaretrospectivestudy AT jesperkoefodpetersen theprevalenceoftumourmarkersinmalignantpleuraleffusionsassociatedwithprimarypulmonaryadenocarcinomaaretrospectivestudy AT gitteandersen theprevalenceoftumourmarkersinmalignantpleuraleffusionsassociatedwithprimarypulmonaryadenocarcinomaaretrospectivestudy AT matteobiagini theprevalenceoftumourmarkersinmalignantpleuraleffusionsassociatedwithprimarypulmonaryadenocarcinomaaretrospectivestudy AT rahulbhatnagar theprevalenceoftumourmarkersinmalignantpleuraleffusionsassociatedwithprimarypulmonaryadenocarcinomaaretrospectivestudy AT christianblaursen theprevalenceoftumourmarkersinmalignantpleuraleffusionsassociatedwithprimarypulmonaryadenocarcinomaaretrospectivestudy AT paulfrostclementsen theprevalenceoftumourmarkersinmalignantpleuraleffusionsassociatedwithprimarypulmonaryadenocarcinomaaretrospectivestudy AT uffebodtger theprevalenceoftumourmarkersinmalignantpleuraleffusionsassociatedwithprimarypulmonaryadenocarcinomaaretrospectivestudy AT katrinefjaellegaard prevalenceoftumourmarkersinmalignantpleuraleffusionsassociatedwithprimarypulmonaryadenocarcinomaaretrospectivestudy AT jesperkoefodpetersen prevalenceoftumourmarkersinmalignantpleuraleffusionsassociatedwithprimarypulmonaryadenocarcinomaaretrospectivestudy AT gitteandersen prevalenceoftumourmarkersinmalignantpleuraleffusionsassociatedwithprimarypulmonaryadenocarcinomaaretrospectivestudy AT matteobiagini prevalenceoftumourmarkersinmalignantpleuraleffusionsassociatedwithprimarypulmonaryadenocarcinomaaretrospectivestudy AT rahulbhatnagar prevalenceoftumourmarkersinmalignantpleuraleffusionsassociatedwithprimarypulmonaryadenocarcinomaaretrospectivestudy AT christianblaursen prevalenceoftumourmarkersinmalignantpleuraleffusionsassociatedwithprimarypulmonaryadenocarcinomaaretrospectivestudy AT paulfrostclementsen prevalenceoftumourmarkersinmalignantpleuraleffusionsassociatedwithprimarypulmonaryadenocarcinomaaretrospectivestudy AT uffebodtger prevalenceoftumourmarkersinmalignantpleuraleffusionsassociatedwithprimarypulmonaryadenocarcinomaaretrospectivestudy
_version_	1718444813206945792

The prevalence of tumour markers in malignant pleural effusions associated with primary pulmonary adenocarcinoma: a retrospective study

Ejemplares similares